Polymorphisms associated with adalimumab and infliximab response in moderate-to-severe plaque psoriasis. - Ovejero-Benito MC, Prieto-Pérez R, Llamas-Velasco M, Muñoz-Aceituno E, Reolid A, Saiz-Rodríguez M, Belmonte C, Román M, Ochoa D, Talegón M, Cabaleiro T, Daudén E, Abad-Santos F (Pharmacogenomics, 2018)